Provided by Tiger Trade Technology Pte. Ltd.

Sagimet Biosciences Inc.

9.14
-0.2300-2.45%
Post-market: 9.260.1246+1.36%19:54 EDT
Volume:1.71M
Turnover:15.58M
Market Cap:648.11M
PE:-7.32
High:9.38
Open:9.26
Low:8.88
Close:9.37
52wk High:11.45
52wk Low:4.50
Shares:70.91M
Float Shares:64.53M
Volume Ratio:0.78
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2490
EPS(LYR):-1.5800
ROE:-24.37%
ROA:-16.41%
PB:2.53
PE(LYR):-5.78

Loading ...

Sagimet Biosciences price target raised to $26 from $25 at Guggenheim

TIPRANKS
·
Oct 02

Sagimet Biosciences Closes Offering of Shares, Warrants

MT Newswires Live
·
Oct 02

Sagimet Biosciences Announces Closing of Underwritten Offering of Series a Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Oct 02

Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Oct 02

Sagimet Biosciences Phase 3 Trial of Denifanstat as Acne Treatment Has High Success Probability, Wedbush Says

MT Newswires Live
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Oppenheimer Adjusts Price Target on Sagimet Biosciences to $38 From $33, Maintains Outperform Rating

MT Newswires Live
·
Oct 01

Sagimet Biosciences Inc. : Oppenheimer Raises Target Price to $38 from $33

THOMSON REUTERS
·
Oct 01

Sagimet Biosciences Announces Major Equity Financing Agreement

TIPRANKS
·
Oct 01

Sagimet Biosciences’ China data strengthens denifanstat case, says Clear Street

TIPRANKS
·
Oct 01

Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell

MT Newswires Live
·
Sep 30

Sagimet Biosciences prices 8.75M shares at $10.00 in underwritten offering

TIPRANKS
·
Sep 30

Sagimet Biosciences - Prices 8.8 Mln Series a Common Shares at $10 Per Share

THOMSON REUTERS
·
Sep 30

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series a Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Sep 30

Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants

GlobeNewswire
·
Sep 30

Sagimet Biosciences - Suspends and Terminates ATM Prospectus Supplement for Series a Common Stock Effective Sept 30

Reuters
·
Sep 30

Sagimet Biosciences - Suspends and Terminates Atm Prospectus Supplement for Series a Common Stock Effective Sept 30 - SEC Filing

THOMSON REUTERS
·
Sep 30

Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial

TIPRANKS
·
Sep 30

Sagimet Reports 52-Week Phase 3 Open-Label Extension Data Showing 56.7% IGA Success for Denifanstat in Moderate to Severe Acne

Reuters
·
Sep 30

Sagimet Biosciences - Denifanstat Well-Tolerated over 52 Weeks with no Serious Adverse Events

THOMSON REUTERS
·
Sep 30